Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy

Martin S. Maron(Beth Israel Deaconess Medical Center), Theodore P. Abraham(Bristol-Myers Squibb (United States)), Stephen B. Heitner(Brigham and Women's Hospital), Aslan T. Turer(The University of Texas Southwestern Medical Center), Sara Saberi(Michigan Medicine), Iacopo Olivotto(Azienda Ospedaliero-Universitaria Careggi), Amy Wohltman(Baim Institute for Clinical Research), Hugh Watkins(John Radcliffe Hospital), Christopher M. Kramer(American College of Cardiology), Anjali Owens(University of Pennsylvania), Caroline Coats(Lahey Medical Center), Albree Tower‐Rader(Massachusetts General Hospital), Timothy C. Wong(University of Pittsburgh), Neal K. Lakdawala(Brigham and Women's Hospital), Scott D. Solomon(Brigham and Women's Hospital), Pablo García‐Pavía(Universidad Francisco de Vitoria), Sharon L. Paige(Cytokinetics (United States)), Ahmad Masri(Oregon Health & Science University), Fady I. Malik(Baim Institute for Clinical Research), Stuart Kupfer(Cytokinetics (United States)), Florian Rader(Twitter (United States)), Michael A. Fifer(Massachusetts General Hospital), Lisa Meng(Cytokinetics (United States)), Lubna Choudhury(Northwestern University), Sherif F. Nagueh(Methodist Hospital), Andrew Wang(Georgia Institute of Technology), Roberto Barriales‐Villa
Journal of the American College of Cardiology
January 1, 2023
Cited by 192


Related Papers